COMMUNIQUÉS West-GlobeNewswire

OrthoPediatrics Corp. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance
05/08/2025
Second Quarter 2025 Revenue Surpasses $60 million for the First Time in Company History, and Increased Adjusted EBITDA by 58% year-over-year WARSAW, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“ [...]
OraSure Announces Second Quarter 2025 Financial Results
05/08/2025
BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure
05/08/2025
Two-year follow-up in Germany Real-World Registry study showed median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure in participants with type 2 diabetes, with no device- or procedure-related [...]
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
05/08/2025
Second quarter total revenue of $166 million, Crysvita ® revenue of $120 million and Dojolvi ® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue [...]
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
05/08/2025
- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05/08/2025
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
OrthoPediatrics Corp. Announces Continued Expansion of Specialty Bracing Division Into New Territories with Multiple Clinics
05/08/2025
WARSAW, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025
05/08/2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30 Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the [...]
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
05/08/2025
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey [...]
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
05/08/2025
M dxh ealth Reports Preliminary Second Quarter 202 5 Results , Reaches Positive Adjusted EBITDA , and A nnounces Acquisition of Exo some D iagnostics B usiness from Bio - Techne Year-over-year Q 2 revenues increased by [...]
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
05/08/2025
OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the second quarter with $453 [...]
Jushi Holdings Inc. Reports Second Quarter 2025 Financial Results
05/08/2025
Revenue of $65.0 million , Reflecting Year-over-Year and Sequential Growth Net Loss of $12.3 million, Compared to $17.0 million in the First Quarter of 2025 Adjusted EBITDA Increased 39.6% Quarter-over-Quarter to $13.7 [...]
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
05/08/2025
NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic [...]
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
05/08/2025
Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage [...]
Pacira BioSciences Reports Second Quarter 2025 Financial Results
05/08/2025
-- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 05, 2025 (GLOBE [...]
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
05/08/2025
Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating [...]
VALNEVA Declaration of shares and voting rights: July 31, 2025
05/08/2025
VALNEVA Declaration of shares and voting rights July 31, 2025 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]
VALNEVA Déclaration d’actions et de droits de vote : 31 juillet 2025
05/08/2025
VALNEVA Déclaration d’actions et de droits de vote 31 juillet 2025 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025
05/08/2025
Aggregated presentation by day and by market Statement of transactions in own shares from July 28th to August 1 st 2025 Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of the transaction [...]

Pages